Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bintrafusp alfa in recurrent and metastatic non-keratinizing nasopharyngeal carcinoma
NCT04396886Phase 2Completed
- Sponsor
- The University of Hong Kong
- Start
- Feb 2020
- Primary completion
- Sep 2022
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bintrafusp alfa in nasopharyngeal carcinoma (NPC), sponsored by The University of Hong Kong. Primary endpoint: Objective Tumour Response at 2 years. Started Feb 2020; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04396886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04396886.